Aclaris TherapeuticsACRS
Recorded

Aclaris Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Roger SongSenior Equity Research Analyst

Welcome to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, Senior Analyst, covers biotech. It is my pleasure to have a fireside chat with our company, Aclaris Therapeutics, and we have our CEO, Neal, and CMO, Jesse.

Neal WalkerCEO

Welcome, gentlemen. Thank you. Thank you for having us.

Roger SongSenior Equity Research Analyst

Awesome. Maybe, Neal, can you just give us state of art of Aclaris? You just announced two news this morning, and where are you now, and where heading to, why you are excited about 2027?

Neal WalkerCEO

Thank you. Sure. This morning we put out two press releases, one announcing that bosakitug, which is our TSLP monoclonal antibody, did not hit the endpoint in atopic dermatitis.

Neal WalkerCEO

This was a little bit of a flyer for us. We were just testing out. We know that TSLP mAb in the past hasn't done well in AD as single agent therapy, and clearly we've shown with the bispecific that the additive benefit of both is important. While disappointing on the clinical front, we did see robust PD responses across the board, particularly on TH1, TH17, and TH2, which was very consistent with the work we did with the bispecific. That was never in our base case plan. Moving forward, our base case plan was to engage in BD on that front.

Neal WalkerCEO

But yeah, we put that out this morning.

Neal WalkerCEO

In addition, we also announced on the oral small molecule side that we have initiated the ATI-2138 modzatinib study in oral lichen planus. That kicked off last week.

Neal WalkerCEO

We are excited about that. Going forward into 2027, and one other thing, we did also comment on the ITK next gen that we have been talking about.

Neal WalkerCEO

We have made it through all of the required tox. Now it is just about pressing the button and filing that this quarter, so that will be in the coming weeks. We are excited about that. Both of those oral small molecule programs open up a lot of value coming into 2027. Moving forward now, we have already talked about, in the last couple weeks, prioritizing EOE as the lead indication for the ATI-052 bispecific. Then we have the ATI-2138 LP study up and running, and that will be in all three phenotypes of lichen planus, mucosal, skin, and scalp.

Neal WalkerCEO

Advancing the ITK next-gen through SAD/MAD work and into POC in 2027.

Roger SongSenior Equity Research Analyst

Excellent. Okay. As you said, I do not think it is that surprising this TSLP alone is not specifically working in the AD. Honestly, you are bold enough to run this trial, and then because you have a probably good TSLP monoclonal antibody. My question is, how much you learn from that phase II, along with your previous single arm trial, and then how much you learn from that, and then you have a higher or lower confidence for your bispecific using the similar construct of the TSLP?

Neal WalkerCEO

Yeah, I still would say it is very high on that front. The ATI-052 data, to me, leveraging the power of the bispecific was unequivocal, and we did take a little bit of a flyer. We did a very small study just to look at the TSLP mAb. The original plan was to do a bigger dose-ranging study. I am glad we did not. I think the fact that it did show activity, it just did not quite have the horsepower, kind of makes sense with the disease. If you leave IL-4 and IL-13 untouched, to keep inflaming the tissue, then it turns out that perhaps TSLP itself does not have enough horsepower to just get it across the finish line.

Neal WalkerCEO

But then when you look at the bispecific construct and you know that IL-4, 13 are leaving some efficacy on the table, what the TSLP is able to do is just take out the front end of that inflammatory cascade, that amplification loop, and then squash that remaining inflammation. We certainly saw that in all of the immune proteome work where we normalized the skin proteome with the bispecific, and we are just getting some of this data in, so I will just comment a little bit on it. We got some Olink data out of the Guttman lab that showed really, really strong biomarker suppression on TH1, TH17, and also on TH2.

Neal WalkerCEO

I think my conclusion at the end of the day was maybe similar to what a lot of folks thought going in, and I think we definitively answered the question about the single agent therapy.

Roger SongSenior Equity Research Analyst

Yeah. Okay. Got it. Basically, the drug that we're supposed to do, but just not really addressing the full spectrum of the atopic dermatitis.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day